Cardiometabolic Disease and Substrate Metabolism

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-45
SponsorUniversity of Tennessee Graduate School of Medicine

About this trial

This study's primary purpose is to determine the potential relationship between cardiometabolic disease, specifically insulin resistance (HOMA-IR), and maternal lipid oxidation.

Eligibility criteria

Qualifiers

Age 18-45

Any pre-pregnancy BMI

At least one high risk OR one moderate risk factor for pre-eclampsia based on ACOG and USPSTF guidelines

Willingness to adhere to aspirin therapy

Disqualifiers

Type 2 Diabetes Mellitus

Type 1 Diabetes Mellitus

Current gestational diabetes mellitus

Current/active platelet disorder or bleeding diathesis (thrombocytopenia of any etiology, idiopathic thrombocytopenic purpura/ITP, thrombotic thrombocytopenic purpura/TTP, von Willebrand disease, etc.)

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

50 Participants
are grouped into 1 trial group